Jo Y.-H. Endogenous BDNF regulates inhibitory synaptic transmission in the ventromedial nucleus of the hypothalamus. J Neurophysiol 107: 42-49, 2012. First published October 12, 2011 doi:10.1152/jn.00353.2011Output from steroidogenic factor-1 (SF-1) neurons in the ventromedial nucleus of the hypothalamus (VMH) is anorexigenic. SF-1 neurons express brain-derived neurotrophic factor (BDNF) that contributes to the regulation of food intake and body weight. Here I show that regulation of GABAergic inputs onto SF-1 neurons by endogenous BDNF determines the anorexigenic outcome from the VMH. Single-cell RT-PCR analysis reveals that one-third of SF-1 neurons express BDNF and that only a subset of BDNF-expressing SF-1 neurons coexpresses the melanocortin receptor type 4. Whole cell patch-clamp analysis of SF-1 neurons in the VMH shows that exogenous BDNF significantly increases the frequency of spontaneous GABAergic inhibitory postsynaptic currents (sIPSCs). This enhancement of GABA drive readily decreases the excitability of SF-1 neurons. However, treatment with BDNF has no significant effect on the frequency of TTX-independent GABAergic IPSCs. Moreover, TrkB receptors are not localized at the postsynaptic sites of GABAergic synapses on SF-1 neurons as there is no change in the amplitude of miniature IPSCs in the presence of BDNF. Dual patch-clamp recordings in mouse hypothalamic slices reveal that stimulation of one SF-1 neuron induces an increase in sIPSC frequency onto the neighboring SF-1 neuron. More importantly, this effect is blocked by a tyrosine kinase inhibitor. Hence, this increased GABA drive onto SF-1 neurons may, in part, explain the cellular mechanisms that mediate the anorexigenic effects of BDNF.
THE VENTROMEDIAL NUCLEUS OF THE HYPOTHALAMUS (VMH) has been considered the brain's "satiety center" as early studies show that lesions of the VMH result in hyperphagia and obesity in a variety of species, including humans (for a review, see King 2006) . Microarray studies (Kurrasch et al. 2007; Segal et al. 2005 ) reveal top marker genes of the VMH, including steroidogenic factor-1 (SF-1; also called Ad4BP and officially designated NR5A1), adenylate cyclase activating polypeptide 1, cerebellin 1 precursor protein (cbln1), etc. Among these genes, SF-1, an orphan nuclear receptor, is critical for the development as well as the physiological functions of the VMH (Davis et al. 2004; Majdic et al. 2002; Tran et al. 2003; Zhao et al. 2008) .
SF-1 appears to be a critical component of overall energy balance. Mice with SF-1 gene knockout are obese , whereas SF-1 heterozygous mice exhibit diet-induced obesity (Tran et al. 2006) . Furthermore, mutations in the SF-1 gene are associated with insulin resistance and type 2 diabetes in Chinese patients (Liu et al. 2006 ). SF-1-expressing neurons in the VMH contribute to the sensing of important regulators of energy balance and are implicated in overall energy homeostasis. For instance, leptin, an adipocyte-derived hormone, alters SF-1 neuronal activity, and loss of leptin receptors in SF-1 neurons increases body weight (Dhillon et al. 2006) . Mice lacking vesicular glutamate transporter in SF-1 neurons develop a modest increase in body weight when fed a high-fat and high-sucrose diet (Tong et al. 2007 ). These findings support previous VMH lesion studies in rodents. However, the cellular mechanisms that mediate the anorexigenic effects remain elusive.
Brain-derived neurotrophic factor (BDNF) and its cognate receptor TrkB are involved in the regulation of food intake and body weight. Perturbed BDNF signaling triggers hyperphagia and obesity in mice (Rios et al. 2001; Unger et al. 2007; . It was demonstrated that a subset of SF-1 neurons in the VMH expresses BDNF (Tran et al. 2006 ) and that SF-1 modulates BDNF gene expression in the VMH (Zhao et al. 2008) . Of particular interest is that BDNF expression in the VMH is regulated by nutrients and nutrient-related signal molecules, including glucose, leptin, and melanocortins (Komori et al. 2006; Unger et al. 2007; Xu et al. 2003) . Moreover, the activation of the melanocortin receptor type 4 (MC4R) induces BDNF release in in vitro preparations (Nicholson et al. 2007 ). Thus, the release of BDNF from SF-1 neurons in response to changes in nutrient status may reduce food intake and body weight.
In this study, I examined the electrophysiological impact of BDNF on inhibitory tone onto SF-1 neurons as inhibitory GABAergic neurons are largely expressed in the nuclei, including the arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), lateral hypothalamus (LH), and ventromedial VMH (Shin et al. 2007) . GABA drive from these local neural circuits is implicated in the control of the excitability of VMH glutamatergic neurons (Fu and van den Pol 2008) . I demonstrated that exogenous BDNF enhanced GABAergic inhibitory synaptic tone onto SF-1 neurons. I further showed that stimulation of one SF-1 neuron readily released BDNF, which in turn regulated inhibitory synaptic transmission onto the neighboring SF-1 neuron. This BDNF-mediated enhancement of GABAergic transmission onto SF-1 neurons may play an important role in the overall regulation of energy homeostasis.
MATERIALS AND METHODS
Animals. All mouse care and experimental procedures were approved by the Institutional Animal Care Research Advisory Committee of the Albert Einstein College of Medicine. Experiments were performed on hypothalamic slices obtained from transgenic mice that selectively express enhanced green fluorescent protein (eGFP) in SF-1-positive neurons in the VMH (a gift from Dr. Keith Parker; Stallings et al. 2002) .
Slice preparation. Transverse brain slices were prepared from transgenic mice at postnatal age 21-28 days. Animals were anesthetized with a mixture of ketamine and xylazine. After decapitation, the brain was transferred into a sucrose-based solution bubbled with 95% O 2 /5% CO 2 and maintained at ϳ3°C. This solution contained the following (in mM): 248 sucrose, 2 KCl, 1 MgCl 2 , 1.25 KH 2 PO 4 , 26 NaHCO 3 , 1 sodium pyruvate, and 10 glucose. Transverse coronal brain slices (200 m) were prepared using a vibratome. Slices were equilibrated with an oxygenated artificial cerebrospinal fluid (aCSF) for Ͼ1 h at 32°C before transfer to the recording chamber. The slices were continuously superfused with aCSF at a rate of 1.5 ml/min containing the following (in mM): 113 NaCl, 3 KCl, 1 NaH 2 PO 4 , 26 NaHCO 3 , 2.5 CaCl 2 , 1 MgCl 2 , and 5 glucose in 95% O 2 /5% CO 2 .
Electrophysiological recordings. Brain slices were placed on the stage of an upright, infrared-differential interference contrast microscope (Olympus BX50WI) mounted on a Gibraltar X-Y table (Burleigh) and visualized with a ϫ40 water-immersion objective by infrared microscopy (DAGE MTI camera). The SF-1 neurons were identified by the presence of eGFP resulting from the transgene. The internal solution contained the following (in mM): 130 CsCl to record GABAergic synaptic currents in voltage clamp configuration (or KCl to record membrane potential in current clamp mode), 5 CaCl 2 , 10 EGTA, 10 HEPES, 2 MgATP, 0.5 Na 2 GTP, and 10 phosphocreatine. All recordings were made at 32 Ϯ 2°C. Membrane currents and potentials were recorded with a Multiclamp 700B in whole cell configuration. GABAergic currents were isolated with the addition of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10 M) and D-aminophosphovaleric acid (D-AP5; 50 M), and glutamatergic synaptic currents were recorded in the presence of picrotoxin (100 M).
Dual patch-clamp recordings were performed on the two SF-1 neurons in the presence of the non-selective metabotropic glutamate receptor (group 1 and 2) antagonist (R,S)-MCPG (500 M; Ascent Scientific); one was current clamped and stimulated by injection of positive currents (10 s of 100 pA) and the other was voltage clamped to monitor GABAergic synaptic activity. Electrophysiological signals were low-pass filtered at 2-5 kHz, stored on a PC, and analyzed offline with pClamp 10 software (Molecular devices) and Mini Analysis software version 6 (Synaptosoft).
CNQX and D-AP5 were purchased from Ascent Scientific and prepared as a 1,000ϫ stock solution. BDNF, K252a, and picrotoxin were purchased from Sigma-Aldrich and prepared as a 1,000ϫ stock solution.
Analysis of spontaneous and miniature IPSCs. Spontaneous miniature inhibitory and excitatory postsynaptic currents (miniature IPSCs and EPSCs) were recorded in the presence of tetrodotoxin (TTX; 1 M; Sigma-Aldrich). Autodetected events with amplitudes of more than Ϫ5 pA and rise time of Ͻ2 ms were also visually examined to correct for noise fluctuation (Mini Analysis software version 6, Synaptosoft). Analysis of miniature IPSC decay phase (Clampfit 10, Molecular Devices) was based on the following criteria: 1) single events only (i.e., no multiple events), 2) events having stable baselines 15 ms before the rise, and 3) smooth transition from 0 current to peak amplitude [Ͻ20% deviation in d(pA)/dt during rise]. Aligned IPSCs were averaged and the decays were fit by a single exponential function.
Single-cell RT-PCR. Single-cell samples were collected from brain slice preparations via aspiration into the patch pipette. The initial reverse transcription (RT) reaction was conducted after pressure ejection of the single-cell samples into freshly prepared RT mix A solution (RT Mix A: 20 units of RNase OUT, 300 ng of random primers, 0.5% Nonidet P-40 and RNase-free water). Samples were sonicated in a total volume of 10 l at 4°C for 5 min and then incubated for 3 min at 65°C prior to addition of 10 l RT mix B (RT mix B: 500 M dNTP, 1ϫ RT buffer, 5 mM MgCl 2 , 10 mM DTT, and 200 units of Superscript II). The tubes were incubated at 25°C for 5 min, at 42°C for 1 h, and at 65°C for 10 min.
Two rounds of amplification were performed for the detection of the MC4R and BDNF transcripts. In the first amplification (final volume 50 l), the reaction mixture contained 10 l of cDNA, 1ϫ PCR buffer with Mg 2ϩ (Roche), 0.2 mM dNTP, 0.1 M of each primer, and 2 units of Taq polymerase (Roche). For the second amplification, the reaction mixtures contained 3 l of the first round PCR product, 1ϫ PCR buffer with Mg 2ϩ (Roche), 0.5 mM dNTP, 1 M of each primer, 1 M of Betaine, and 2 units of Taq polymerase in a final volume of 30 l. Following denaturation for 3 min at 94°C, the target cDNAs were amplified for 35 cycles (94°C, 30 s; 60°C, 30 s; 72°C, 30 s) followed by 10 min at 72°C. After amplification, the PCR products were analyzed on 2% agarose gels. The sequences of the primers used are the following: BDNF forward: 5=-CCTCCTC-TACTCTTTCTGCTG-3=; BDNF reverse outer : 5=-TGTCTATCCT-TATGAATCGCCA-3=; BDNF reverse inner : 5=-TGACCCACTCGC-TAATACTG-3=; MC4R forward: 5=-TAGCCAAGAACAAGAAC-CTG-3=; MC4R reverse outer : 5=-CTGTCCGAGTAAATGATGAA-GAG-3=; MC4R reverse inner : 5=-ACAACTTATGATGATCCCGA-3=; all primers were purchased from Invitrogen (Carlsbad, CA) and amplified at equivalent efficiencies.
Statistics. Statistical analyses were performed on all SF-1 GFP neurons examined using the paired t-test (Origin 7.0, OriginLab). The mean values were reported from the entire population tested. The Kolmogorov-Smirnov test was used to compare the cumulative distribution of the data (Origin 8.5, OriginLab). Data were considered significantly different when the P value was Ͻ0.05. All statistical results are given as means Ϯ SE.
RESULTS

BDNF enhances GABAergic synaptic transmission.
BDNF signaling in the VMH is important in regulating overall energy balance (Unger et al. 2007; Xu et al. 2003) , and the synthesis and release of BDNF from VMH neurons are regulated by melanocortins (Nicholson et al. 2007; Xu et al. 2003) . I first sought to determine which fraction of SF-1 neurons within the VMH (Fig. 1A) expressed the MC4R and BDNF. Single-cell RT-PCR assay showed that approximately one-third of SF-1 neurons expressed BDNF mRNA (n ϭ 10 out of 30 neurons; Fig. 1B ) and 20% of SF-1 neurons were positive for MC4R mRNA (n ϭ 8 out of 40 neurons; Fig. 1B ). The coexpression of BDNF and MC4R, however, was observed only in a very small subset of SF-1 neurons (n ϭ 1 out of 30 BDNF-positive SF-1 neurons; Fig. 1B ). These findings are in agreement with a previous study (Tran et al. 2006) showing that only a subpopulation of SF-1 neurons in the VMH coexpresses BDNF, although more than half of BDNF-expressing neurons in the VMH coexpress SF-1.
To study the electrophysiological impact of BDNF on SF-1 neurons, I examined the effect of BDNF on GABAergic sIPSCs onto SF-1 neurons. I isolated GABA A receptor-mediated sIPSCs, which were blocked by the GABA A receptor antagonist picrotoxin (100 M). Treatment with BDNF (20 ng/ml) induced a robust enhancement of GABAergic transmission onto SF-1 neurons (Fig. 1, C and D) . BDNF significantly increased the mean frequency of sIPSCs (Fig. 1, D and E; mean sIPSC frequency: control: 9.8 Ϯ 2.8 Hz, BDNF: 14.0 Ϯ 3.4 Hz; n ϭ 9 neurons, P Ͻ 0.05). This enhancement was associated with an increase in the mean amplitude of sIPSCs ( Fig.  1F ; mean sIPSC amplitude: control: Ϫ106.8 Ϯ 19.7 pA, BDNF: Ϫ127.7 Ϯ 19.5 pA; n ϭ 9 neurons, P Ͻ 0.05), and this effect was reversible during recordings (Fig. 1D) . BDNF- induced enhancement was completely blocked by the tyrosine kinase inhibitor K252a (100 nM; mean sIPSCs frequency: K256a: 5.4 Ϯ 1.6 Hz, K256a ϩ BDNF: 6.0 Ϯ 1.8 Hz, n ϭ 7 neurons, P Ͼ 0.05; mean sIPSCs amplitude: K256a: Ϫ85.6 Ϯ 11.8 pA, K256a ϩ BDNF: Ϫ85.3 Ϯ 11.5 Hz, n ϭ 7 neurons, P Ͼ 0.05). These results suggest that BDNF increases GABA drive to SF-1 neurons.
I then examined whether BDNF induced any changes in action potential frequency in SF-1 neurons since BDNF enhanced inhibitory GABAergic tone onto SF-1 neurons. Treatment with BDNF (20 ng/ml) significantly attenuated the mean firing rate of the neurons examined (Fig. 1, G-I ; mean action potential frequency: control: 2.5 Ϯ 0.7 Hz, BDNF: 1.1 Ϯ 0.4 Hz; n ϭ 12 neurons, P Ͻ 0.05; mean membrane potential: control: Ϫ44.7 Ϯ 1.5 mV, BDNF: Ϫ46.0 Ϯ 1.8 mV; n ϭ 12 neurons, P Ͼ 0.05). It thus appears that BDNF-mediated increase in GABA tone eventually modulates the excitability of SF-1 neurons. Fig. 2 . BDNF has no effect on miniature GABAergic IPSCs onto SF-1 neurons. A: representative recording samples showing miniature IPSCs recorded in SF-1 GFP-positive neurons. There was no change in the frequency of miniature IPSCs after treatment with BDNF (20 ng/ml; A1). HP ϭ Ϫ70 mV. A2: on the expanded time scale. A3: cumulative probability of miniature IPSC amplitude and interevent interval. The cumulative probability distributions of miniature IPSC interevent interval and amplitude did not significantly differ before and after treatment with BDNF. Right inset: superimposition of normalized traces of average amplitude of miniature IPSCs before and after treatment with BDNF. No difference in the decay was observed. B-D: pooled data of the frequency, amplitude, or decay of miniature IPSCs recorded from 9 different neurons. No significant differences were observed in these parameters. E: BDNF had no effect on the firing rate of SF-1 GFP-positive neurons without synaptic influences. Treatment with BDNF (20 ng/ml) neither depolarized nor increased the frequency of action potential discharge. Vm ϭ Ϫ45 mV.
BDNF doesn't modulate miniature inhibitory GABAergic currents onto SF-1 neurons.
To determine the cellular mechanisms that mediate an increased GABA drive by BDNF onto SF-1 neurons, I examined the effects of BDNF on miniature IPSCs. In the presence of TTX (1 M), which blocks neuronal network activity, treatment with BDNF (20 ng/ml) had no effect on miniature IPSCs (Fig. 2, A1-A3 ). Neither the mean frequency nor the mean amplitude of miniature IPSCs was modulated following application of BDNF (Fig. 2, B-D ; frequency: before: 1.6 Ϯ 0.3 Hz, after: 1.6 Ϯ 0.3 Hz; n ϭ 7 neurons; amplitude: before: Ϫ44.0 Ϯ 1.6 pA, after: Ϫ44.1 Ϯ 2.2 pA, n ϭ 7 neurons, P Ͼ 0.05). Furthermore, the mean decay time of miniature IPSC was not changed with or without BDNF (before: 14.8 Ϯ 2.1 ms, after: Ϫ16.1 Ϯ 2.3 ms, n ϭ 7 neurons, P Ͼ 0.05). Moreover, my initial experiments revealed that BDNF had no effect on miniature EPSCs (mean miniature EPSC frequency: before: 1.8 Ϯ 1.3 Hz, after: 2.0 Ϯ 1.5 Hz; mean miniature EPSC amplitude: before: Ϫ13.4 Ϯ 3.1 pA, Fig. 3 . Modulation by their own peptides of spontaneous GABAergic transmission onto SF-1 neurons. A: representative recording samples showing that 10 s of depolarization of 1 SF-1 neuron by a positive current injection (100 pA) evoked action potential discharge and that this firing increased spontaneous IPSC frequency recorded from the neighboring SF-1 neuron (A1, top). Bottom: on the expanded timescale. HP ϭ Ϫ70 mV. A2: histogram shows the normalized frequency of sIPSCs before, during, and after stimulation of SF-1 neuron shown in A1. This effect was readily reversible. B: pooled data of the frequency or amplitude of sIPSCs recorded from 5 different neurons. These parameters were significantly different (*P Ͻ 0.05). C: representative recording samples showing that K252a (100 nM) completely blocked stimulation-induced enhancement of GABAergic transmission onto SF-1 neurons (C1, top). HP ϭ Ϫ70 mV. Bottom: on the expanded timescale. C2: histogram shows the normalized frequency of sIPSCs before, during, and after stimulation of SF-1 neuron shown in C1. sIPSC frequency remained stable before and after stimulation of 1 SF-1 neuron in the presence of the tyrosine kinase inhibitor K252a. All experiments were performed in the presence of (R,S)-MCPG (500 M) to prevent involvement of metabolic glutamate receptors. D: pooled data of the frequency or amplitude of sIPSCs recorded from 11 different neurons in the presence of K252a. No significant differences were observed in these parameters. after: Ϫ14.5 Ϯ 2.6 pA; n ϭ 3 neurons, P Ͼ 0.05). It thus appears that TrkB receptors are not localized at the postsynaptic sites of GABAergic and glutamatergic synapses on SF-1 neurons since there was no change in the amplitude of miniature IPSCs and EPSCs in the presence of BDNF.
I further examined the direct action of BDNF on SF-1 neurons by measuring membrane potential (Vm) in current clamp mode following blockade of excitatory and inhibitory synaptic transmission. Treatment with BDNF (20 ng/ml) had no effect on the membrane potential and the firing rate of SF-1 neurons ( Fig. 2E ; firing rate: before: 4.0 Ϯ 1.4 Hz, after: 3.8 Ϯ 1.3 Hz, n ϭ 6 neurons, P Ͼ 0.05; Vm: before: Ϫ49.7 Ϯ 3.6 mV, after: Ϫ50.4 Ϯ 1.8 mV, n ϭ 6 neurons, P Ͼ 0.05). These results suggest that SF-1 neurons do not express TrkB receptors.
Stimulation of SF-1 neurons releases BDNF. To investigate whether SF-1 neurons use BDNF as an excitatory neuromodulator that regulates synaptic activity onto SF-1 neurons, dual patch-clamp recordings were performed on the two SF-1 neurons in the VMH (Fig. 3) . One SF-1 neuron was current clamped and stimulated by injection of positive currents. GABAergic IPSCs were collected from the neighboring SF-1 neuron. Injection of positive currents (100 pA) for 10 s into SF-1 neurons evoked action potential discharge (Fig. 3A1 ). This manipulation readily enhanced spontaneous GABAergic IPSCs in approximately one-half of the neurons examined (Fig.  3, A1 and A2 ; n ϭ 5 out of 9 neurons). Both sIPSC frequency and amplitude were significantly increased following 10 s of stimulation ( Fig. 3B ; mean sIPSC frequency: before: 4.6 Ϯ 2.0 Hz, after: 6.9 Ϯ 2.5 Hz; n ϭ 5 neurons; P Ͻ 0.05; mean sIPSC amplitude: before Ϫ39.9 Ϯ 3.0 pA, after Ϫ53.1 Ϯ 4.3 pA; n ϭ 5 neurons; P Ͻ 0.05). Importantly, this enhancement was completely blocked by the tyrosine kinase inhibitor K252a (100 nM). Such a stimulation had no effect on GABAergic transmission in the presence of K252a (Fig. 3, C1 , C2, and D; mean sIPSC frequency: before 9.8 Ϯ 2.5 Hz, after 10.2 Ϯ 2.6 Hz; mean sIPSC amplitude: before Ϫ78.2 Ϯ 13 pA after Ϫ79.2 Ϯ 14 pA; n ϭ 11 neurons; P Ͼ 0.05). These findings suggest that depolarization of SF-1 neurons induces BDNF release, which in turn regulates GABAergic inhibitory tone onto SF-1 neurons.
DISCUSSION
This current study provides physiological evidence that a subset of SF-1 neurons expresses BDNF and that GABAergic synaptic inputs onto SF-1 neurons are regulated by exogenous and endogenous BDNF. The activation of TrkB receptors by BDNF readily enhances inhibitory tone onto SF-1 neurons. This increased GABA drive eventually modulates the excitability of SF-1 neurons. The enhancement of GABAergic transmission appears to be presynaptic in origin as BDNF has no effect on miniature GABAergic IPSCs. Direct stimulation of one SF-1 neuron releases endogenous BDNF, and subsequent TrkB receptor activation enhances GABAergic transmission onto the neighboring SF-1 neurons. Although BDNF is a key component of neuronal development, this work suggests that a rapid action on GABAergic inhibitory tone onto SF-1 neurons may explain, in part, the cellular mechanisms that mediate the anorexigenic effects of BDNF.
BDNF is expressed at high levels in the VMH and its expression in the VMH is regulated by nutritional status as wells as by melanocortin signaling . It was demonstrated that a subset of SF-1 neurons in the VMH expresses BDNF (Tran et al. 2006) . Given that the expression of BDNF in the VMH is regulated by melanocortin signaling, I expected the coexpression of BDNF and MC4Rs in SF-1 neurons. Coexpression of BDNF and MC4Rs in SF-1 neurons, however, was rare. It is thus possible that regulation by melanocortins of BDNF expression in SF-1 neurons involves additional neurons that may reside within and/or outside of the VMH. In fact, the levels of MC4R expression in the VMH are relatively low compared with other hypothalamic nuclei (Kishi et al. 2003) . Alternatively, melanocortin signaling may directly modulate BDNF expression in non-SF-1 neurons in the VMH since only ϳ10% of SF-1 neurons express BDNF, although more than half of BDNF-positive VMH neurons are SF-1 positive (Tran et al. 2006) .
The excitability of VMH neurons, including SF-1 neurons, is regulated by leptin, agouti-related peptide, and melanocortins (Dhillon et al. 2006; Fu and van den Pol 2008) . In this work, I demonstrated that electrical stimulation of a single SF-1 neuron readily induced the release of BDNF. Hence, it is possible that altered excitability of SF-1 neurons in response to nutrients and nutrient-related signaling molecules could trigger the release of BDNF into the hypothalamic neural circuits. Subsequently, this released BDNF would regulate TrkB-expressing neurons. The identity of TrkB-expressing hypothalamic neurons, however, remains to be determined. It appears that few arcuate and lateral hypothalamic neurons, including orexin, melanin-concentrating hormone, cocaine-and amphetamine-regulated transcript (CART), and neuropeptide Y neurons express TrkB, although TrkB-expressing neurons are found in these nuclei . Immunocytochemistry assay reveals that BDNF induces c-fos expression in the paraventricular nucleus (PVN), dorsomedial nucleus (DMH), and VMH (Unger et al. 2007 ). In addition, it was described that the VMH has direct connections with the PVN and the DMH (Tran et al. 2003; Williams et al. 2001) . Thus, it is plausible that PVN and DMH neurons respond to BDNF released from VMH SF-1 neurons and reciprocally regulate the excitability of SF-1 neurons by increasing inhibitory tone onto SF-1 neurons (Fig. 4) . Alternatively, local GABAergic circuits within and outside the VMH (Shin et al. 2007 ) may be responsible for this effect. In fact, neurons in the VMH produce approximately three primary dendrites, with the longest primary dendrites (Ͼ200 M) extending outside the VMH, and the short primary dendrites, which remain within the borders of the VMH, presumably to be innervated by local interneurons (Griffin and Flanagan-Cato 2011) .
Of particular interest is that BDNF can be secreted from dendrites or axonal terminals (Horch and Katz 2002; Matsuda et al. 2009 ). BDNF secretion from axons and dendrites appears to be differentially regulated in an activity-dependent manner (Matsuda et al. 2009 ). This may imply that SF-1 neuron activity differentially regulates BDNF-TrkB signaling between SF-1 and neurons in the target areas via BDNF release from short and long dendrites and axons. For instance, local release of BDNF from dendrites following high frequency activity could influence the excitability of VMH and DMH neurons, whereas brief spiking could trigger the release of BDNF from axons in target areas within and/or outside of the hypothalamus, including the PVN, the bed nucleus of stria terminals, and the amygdala. This activity-dependent BDNF release may explain, in part, the differential roles of BDNF-expressing SF-1 neurons in the regulation of anxiety and depression (Zhao et al. 2008 ) vs. energy balance (Tran et al. 2006) .
BDNF promotes survival and differentiation of neurons in both developing and adult central nervous system (for a review, see Lipsky and Marini 2007) and participates in the formation of appropriate synaptic connections (for a review, see Cohen-Cory et al. 2010) . Therefore, neurodevelopmental anomalies may contribute to the obesity phenotype observed in BDNF and TrkB mutant animals (Fox and Byerly 2004; Kernie et al. 2000; Lyons et al. 1999; Xu et al. 2003) . In contrast to these long-term effects of BDNF on the establishment of hypothalamic neural circuitry, there are several studies showing the acute effects of BDNF on body weight and food intake. For instance, infusion of BDNF into the third ventricle reverses obesity in BDNF heterozygous mutant mice (Kernie et al. 2000) . Intraperitoneal administration of BDNF significantly reduces food intake and improves glucose tolerance in dietinduced obesity and diabetic mice (Nakagawa et al. 2003) . Additionally, a single intrahypothalamic infusion of a TrkB agonist reduces food intake and body weight in mice (Tsao et al. 2008) . Hence, the observed electrophysiological action of BDNF on inhibitory tone onto SF-1 neurons may be involved in the regulation of overall energy homeostasis. Importantly, nutrient-related signaling molecules regulate BDNF expression in the VMH (Komori et al. 2006; Unger et al. 2007; Xu et al. 2003) . In particular, the activation of central melanocortinergic signaling modulates BDNF expression and induces its release (Nicholson et al. 2007 ). Thus, the release of BDNF from SF-1 neurons in response to changes in nutrient status may play a key role in the control of energy balance.
In summary, the synthesis and release of endogenous BDNF from SF-1 neurons in the VMH can be regulated by diverse factors, including nutritional status and nutrients-related signals. The responses of BDNF-expressing SF-1 neurons to these physiological cues could result in the anorexigenic effects. These studies thus provide not only novel insights into the physiological functions of BDNF-expressing SF-1 neurons, but also molecular targets within the VMH that may eventually pave the way for the development of therapies for obesity and obesity-related diseases.
